A booster dose (50 ug) of mRNA-1273.351, the company's strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant prevalent in South African than a booster dose of its other candidate, mRNA-1273, according to the company.

A manuscript describing the preliminary results has been submitted as a preprint to bioRxiv and will be submitted for peer-reviewed publication upon completion of the multivalent mRNA-1273.211 booster arm, Moderna reported.

Moderna increases manufacturing capacity
Moderna has doubled the size of its manufacturing technology center in Norwood, MA, expanding the facility from a production and lab space into an industrial...

Moderna secures WHO emergency use listing for COVID-19 vaccine
Moderna has secured emergency use listing from the World Health Organization (WHO) for its COVID-19 vaccine.

DNA Script, Moderna to develop on-demand vaccines, therapeutics
DNA Script and Moderna have announced a partnership to develop on-demand vaccines and therapeutics as part of the U.S. Defense Advanced Research Projects...

Sanofi to provide fill/finish services for Moderna COVID-19 vaccine
Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine.

Moderna provides updates on mRNA vaccine platform
Moderna gave updates on its messenger RNA (mRNA) vaccines during its second annual Vaccines Day event. The company plans to continue to invest resources...